News | Stent Grafts | April 06, 2017

Endologix Announces Enrollment of First Patients in ELEVATE IDE Clinical Study

Trial will evaluate safety and effectiveness of Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms

April 6, 2017 — Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study.

ELEVATE IDE is the company’s pivotal clinical trial to evaluate the safety and effectiveness of the Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms (AAAs). The trial is approved to enroll 75 patients at up to 12 centers in the United States. The first procedure was performed by Steve Henao, M.D., chief, Division of Vascular Surgery at New Mexico Heart Institute.

The study principal investigator, Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic commented, “We are excited to start treating patients in the ELEVATE IDE trial. The polymer technology in the device allows for active sealing in the aortic neck. The polymer sealing ring has proven durability in maintaining aneurysm exclusion to five years as reported in the Global Ovation Pivotal Trial. The repositioning of the sealing ring to 7mm below the top of the fabric will allow treatment of more challenging and complex anatomies in this trial.”

Ovation Alto is the newest device in the Ovation platform of abdominal stent graft systems, which has proven clinical results reported from the Ovation global pivotal trial and European Post-Market Registry. Ovation Alto expands endovascular aortic repair (EVAR) to treat more patients on IFU. This is achieved by the conformable O-rings with CustomSeal polymer that have been repositioned near the top of the endograft, providing seal just below the renal arteries.

The Ovation platform is the lowest profile U.S. Food and Drug Administration (FDA)-approved EVAR device, and it has been used successfully in the treatment of over 12,000 patients worldwide. Ovation Alto is an investigational device and currently not approved in any market.

Endologix CEO John McDermott said the company expects Ovation Alto could be available in the U.S. in 2019, based on the anticipated enrollment timeline.

For more information: www.endologix.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init